Future MS care: A consensus statement of the MS in the 21st Century Steering Group

Journal of Neurology

Volumn 260, Issue 2, 2013, Pages 462-469

  Rieckmann, Peter ^a   Boyko, Alexey ^b   Centonze, Diego ^c   Coles, Alasdair ^d   Elovaara, Irina ^e   Havrdová, Eva ^f   Hommes, Otto ^g   Lelorier, Jacques ^h   Morrow, Sarah A ⁱ   Oreja Guevara, Celia ^j   Rijke, Nick ^k   Schippling, Sven ^l  

^a Sozialstiftung Bamberg Hospital   (Germany)

^b Moscow MS Center 11 City Hospital Department of Neurology and Neurosurgery of the RSMRU   (Russian Federation)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f CHARLES UNIVERSITY   (Czech Republic)

^g European Charcot Foundation   (Netherlands)

^h Pavillon Masson ^*  (Canada)

ⁱ UNIVERSITY OF WESTERN ONTARIO   (Canada)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k MS Society   (United Kingdom)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Care; Consensus statement; Management; Multiple sclerosis

Indexed keywords

ARTICLE; BASIC RESEARCH; CLINICAL TRIAL (TOPIC); CONSENSUS; DISABILITY; DISEASE COURSE; FUNDING; HUMAN; LICENSING; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ADVOCACY; PATIENT CARE; PATIENT INFORMATION; PATIENT SAFETY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; REIMBURSEMENT; RELAPSE;

CANADA; CONSENSUS; DECISION MAKING; DISEASE MANAGEMENT; EUROPE; HUMANS; MULTIPLE SCLEROSIS; PATIENT-CENTERED CARE; RESEARCH;

EID: 84876491216     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6656-6     Document Type: Article

References (48)

1. European MS Platform. Code of good practice in MS. (2008) Available at: www.emsp.org
2. National Institute of Neurological Disorders and Stroke. NINDS multiple sclerosis information page. National Institutes of Health. http://www.ninds.nih. gov/disorders/multiple-sclerosis/multiple-sclerosis.htm. Accessed: December 27 2010
3. Kobelt G, Lindgren P, Smala A, Rieckmann P, and the German Cost of MS Study Group (2001) Cost and quality of life in multiple sclerosis. Health Econ Prev Care 2:60-68
4. Flachenecker P, Khil L, Bergmann S, Kowalewski M, Pascu I, Perez-Miralles F, Sastre-Garriga J, Zwingers T (2010) Development and pilot phase of a European MS register. J Neurol 257:1620-1627
5. Costello K, Kennedy P, Scanzillo J (2008) Recognizing non-adherence in patients with multiple sclerosis and maintaining treatment adherence in the long term. Medscape J Med 10:225
6. Courts NF, Newton AN, McNeal LJ (2005) Husbands and wives living with multiple sclerosis. J Neurosci Nurs 37:20-27
7. de Seze J, Borgel F, Brudon F (2012) Patient perceptions of multiple sclerosis and its treatment. Patient Prefer Adherence 6:263-273
8. Lugaresi A, Ziemssen T, Oreja-Guevara C, Thomas D, Verdun E (2012) Improving patient-physician dialog: commentary on the results of the MS Choices survey. Patient Prefer Adherence 6:143-152
9. Kieseier BC, Wiendl H, Hartung HP, Stuve O (2009) The future of multiple sclerosis therapy. Pharmacol Res 60:207-211
10. Giovannoni G, Rhoades RW (2012) Individualizing treatment goals and interventions for people with MS. Current Opin Neurol 25(Suppl):S20-S27
11. National Institute for Clinical Excellence (2003) Mult Scler. Management of multiple sclerosis in primary and secondary care. Clinical Guideline 8. Available at: http://www.nice.org.uk/nicemedia/live/10930/29199/29199.pdf
12. Oreja-Guevara C, Miralles A, Garcia-Caballero J, Noval S, Gabaldon L, Esteban-Vasallo MD, Garcia-Matres MJ, Bayon-Perez C, Royo A, Gonzalez A, Hernanzi A, Lopez-Pajares MR, Morante JL, Diez-Tejedor E (2010) Clinical pathways for the care of multiple sclerosis patients. Neurologia 25:156-162 (Barcelona, Spain)
13. Stuart WH (2004) Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management. J Manag Care Pharm 10:S19-S25
14. Heesen C, Solari A, Giordano A, Kasper J, Kopke S (2011) Decisions on multiple sclerosis immunotherapy: new treatment complexities urge patient engagement. J Neurol Sci 306:192-197
15. Kopke S, Richter T, Kasper J, Muhlhauser I, Flachenecker P, Heesen C (2012) Implementation of a patient education program on multiple sclerosis relapse management. Patient Educ Couns 86:91-97
16. Solari A, Martinelli V, Trojano M, Lugaresi A, Granella F, Giordano A, Messmer Uccelli M, D'Alessandro R, Pucci E, Confalonieri P, Borreani C (2010) An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care. Mult Scler 16:1393-1405
17. Benbow CL, Koopman WJ (2003) Clinic-based needs assessment of individuals with multiple sclerosis and significant others: implications for program planning-psychological needs. Rehabil Nurs 28:109-116
18. Costa DC, Sa MJ, Calheiros JM (2012) The effect of social support on the quality of life of patients with multiple sclerosis. Arq Neuropsiquiatr 70:108-113
19. Hwang JE, Cvitanovich DC, Doroski EK, Vajarakitipongse JG (2011) Correlations between quality of life and adaptation factors among people with multiple sclerosis. Am J Occup Ther 65:661-669
20. Malcomson KS, Dunwoody L, Lowe-Strong AS (2007) Psychosocial interventions in people with multiple sclerosis: a review. J Neurol 254:1-13
21. Rinon A, Buch M, Holley D, Verdun E (2011) The MS Choices Survey: findings of a study assessing physician and patient perspectives on living with and managing multiple sclerosis. Patient Prefer Adherence 5:629-643
22. Simmons RD (2010) Life issues in multiple sclerosis. Nat Rev 6:603-610
23. Federsel HJ (2010) Process R and D under the magnifying glass: organization, business model, challenges, and scientific context. Bioorg Med Chem 18:5775-5794
24. US DHHS, FDA, CDER, CBER (2005) Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. http://www.fda.gov/downloads/regulatoryinformation/guidances/ucm126834.pdf. Accessed 30 May 2012
25. US DHHS, FDA, CDER, CBER (2005) Guidance for industry: premarketing risk assessment. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ ucm126958.pdf. Accessed 30 May 2012
26. Berg J, Lindgren P, Fredrikson S, Kobelt G (2006) Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 7(2):S75-S85
27. Blahova Dusankova J, Kalincik T, Dolezal T, Kobelt G, Havrdova E (2012) Cost of multiple sclerosis in the Czech Republic: the COMS study. Mult Scler 18:662-668
28. Kobelt G (2006) Costs and quality of life for patients with multiple sclerosis in Belgium. Eur J Health Econ 7(2):S24-S33
29. Kobelt G, Berg J, Lindgren P, Anten B, Ekman M, Jongen PJ, Polman C, Uitdehaag B (2006) Costs and quality of life in multiple sclerosis in the Netherlands. Eur J Health Econ 7(2):S55-S64
30. Kobelt G, Berg J, Lindgren P, Battaglia M, Lucioni C, Uccelli A (2006) Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 7(2):S45-S54
31. Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, Konig N, Limmroth V, Straube E (2006) Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 7(2):S34-S44
32. Kobelt G, Berg J, Lindgren P, Gerfin A, Lutz J (2006) Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 7(2):S86-S95
33. Kobelt G, Berg J, Lindgren P, Izquierdo G, Sanchez-Solino O, Perez-Miranda J, Casado MA (2006) Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 7(2):S65-S74
34. Kobelt G, Berg J, Lindgren P, Jonsson B (2006) Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 7(2):S5-S13
35. Kobelt G, Berg J, Lindgren P, Kerrigan J, Russell N, Nixon R (2006) Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 7(2):S96-S104
36. Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, Kolleger H, Vass K (2006) Costs and quality of life of multiple sclerosis in Austria. Eur J Health Econ 7(2):S14-S23
37. Sobocki P, Pugliatti M, Lauer K, Kobelt G (2007) Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Scler 13:1054-1064
38. Hartung HP, Aktas O (2011) Evolution of multiple sclerosis treatment: next generation therapies meet next generation efficacy criteria. Lancet Neurol 10:293-295
39. Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Eng J Med 359:1786-1801
40. Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA (2011) Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 10:338-348
41. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. New Eng J Med 362:416-426
42. Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sorensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S (2011) Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post hoc and subgroup analysis. Lancet Neurol 10:329-337
43. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R (2009) Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab safety and efficacy in relapsing-remitting multiple sclerosis (AFFIRM) study. Lancet Neurol 8:254-260
44. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Eng J Med 354:899-910
45. Cohen JA, Reingold SC, Polman CH, Wolinsky JS (2012) Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 11:467-476
46. Sormani MP, Stubinski B, Cornelisse P, Rocak S, Li D, De Stefano N (2011) Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis. Mult Scler 17:541-549
47. Sormani MP, Bonzano L, Roccatagliata L, De Stefano N (2011) Magnetic resonance imaging as surrogate for clinical endpoints in multiple sclerosis: data on novel oral drugs. Mult Scler 17:630-633
48. Lage A (2011) Global pharmaceutical development and access: critical issues of ethics and equity. MEDICC review 13:16-22